Name: RNAZ Balance Sheet - Transcode Therapeutics Assets & Debt | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Total Assets, Current Assets, Cash and Equivalents, Total Liabilities, Long-term Debt, Short-term Debt, Shareholders Equity, Working Capital, Book Value Per Share

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

RNAZ - Transcode Therapeutics, Inc.

USD | NASDAQ | Healthcare

RNAZ Balance Sheet - Transcode Therapeutics Assets & Debt | Ledgeburg

(in millions of USD)	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Cash And Short Term Investments
Cash And Equivalents	17.8	5.8	2.8	5.0	20.8	0.8	-
Restricted Cash	-	-	-	-	-	-	-
Short Term Investments	-	-	-	-	-	-	-
Cash And Short Term Investments	17.8	5.8	2.8	5.0	20.8	0.8	-
Receivables
Accounts Receivable	-	-	-	-	-	-	-
Current Assets
Inventory	-	-	-	-	-	-	-
Prepaid Expenses	0.9	1.3	1.7	2.1	1.9	0.0	-
Non-Current Assets
Property, Plant & Equipment Gross	0.8	0.4	0.4	0.3	-	-	-
Accumulated Depreciation	0.4	0.3	0.3	0.1	0.0	-
Current Liabilities
Accounts Payable	-	-	-	-	-	-	-
Short Term Debt	-	-	-	-	-	-	-
Non-Current Liabilities
Long Term Debt	-	-	-	-	-	-	-
Operating Lease Liabilities Non-Current	-	-	0.0	-	-	-
Common Equity
Common Stock	0.0	0.0	0.0	0.0	0.0	0.0	-
Additional Paid In Capital	108.2	61.2	48.1	31.1	30.7	0.1
Supplementary Data
Total Debt	-	-	-	-	-	-	-
Net debt	-	-	-	-	-	-	-

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21	Q4 FY 20	Q3 FY 20	Q2 FY 20	Q1 FY 20	Q4 FY 19
Cash And Short Term Investments
Cash And Equivalents	12.8	17.8	2.8	7.4	11.6	5.8	1.9	3.4	4.9	2.8	7.5	3.6	1.6	5.0	8.8

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Non-Current Liabilities
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Lease Liabilities Non-Current	-	-	-	-	-	-	-	-	-	0.0	0.2	0.3	0.4	-	-	-
Deferred Revenue Non-Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Tax Liabilities	0.5	0.2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pension Obligations	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Non-Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities	7.3	7.0	0.8	0.6	0.4	6.5	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	12.6	10.5	3.8	2.1	2.9	9.3	2.3	3.5	2.7	3.5	5.8	3.8	5.8	4.3	3.8	1.7

Common Equity
Common Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-	0.0	-	-	-	-
Additional Paid In Capital	116.9	108.2	85.8	85.7	85.6	61.2	58.9	56.3	54.3	48.1	46.8	39.1	32.4	31.1	31.0	30.9	30.8
Retained Earnings	(115.6)	(97.9)	(84.4)	(79.6)	(75.3)	(63.2)	(57.3)	(54.9)	(49.7)	(46.4)	(42.3)	(37.0)	(32.7)	(27.9)	(22.7)	(18.4)	(13.8)
Accumulated Other Comprehensive Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Treasury Stock	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Stockholders Equity	1.3	10.3	1.4	6.1	10.3	(2.0)	1.7	1.3	4.6	1.6	4.4	2.1	(0.2)	3.2	8.2	12.4	17.0
Total Equity	1.3	10.3	1.4	6.1	10.3	(2.0)	1.7	1.3	4.6	1.6	4.4	2.1	(0.2)	3.2	8.2	12.4	17.0	20.4

Supplementary Data
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Working Capital	11.4	18.5	1.8	6.7	10.5	4.3	1.3	0.9	4.0	1.0	3.8	1.4	(1.1)	3.0	7.8	12.2	16.8	20.2
Book Value	1.3	10.3	1.4	6.1	10.3	(2.0)	1.7	1.3	4.6	1.6	4.4	2.1	(0.2)	3.2	8.2	12.4	17.0	20.4
Tangible Book Value	(138.8)	(129.7)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-